Photodynamic therapy comprises a photosensitising agent, which accumulates in malignant tissue, and a light source, which activates the photosensitiser, causing it to generate highly reactive oxygen species that destroy malignant cells. Temoporfin is a second generation photosensitiser that has a shorter half life than its predecessors and is thought to be more selective towards tumours. These two factors should decrease the incidence of photosensitivity, one of the main side effects …
No takes yet. Share an insight, caveat, or question.
Shehan Hettiaratchy (2000) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: